634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)

類似資料

• 491 BASECAMP-1: an observational study to identify relapsed solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) and leukapheresis for future CAR T-cell therapy
  著者:: Yi Lin, 等
  出版事項: (2021-11-01)
• 634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)
  著者:: Sarah Nikiforow, 等
  出版事項: (2023-11-01)
• BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials
  著者:: Sarah Nikiforow, 等
  出版事項: (2026-03-01)
• Loss of heterozygosity (LOH)--implications for human genetic identification.
  著者:: Jerzy Janica, 等
  出版事項: (2009-05-01)
• Direct inference of SNP heterozygosity rates and resolution of LOH detection.
  著者:: Xiaohong Li, 等
  出版事項: (2007-11-01)